Bristol-Myers Squibb (BMY)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Oncologysrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-10-13. ClinicalTrials.gov
Dilution Risk
LOW DILUTION RISKDilution score: 10/100 (LOW), cash runway not available
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: 2.25% of float, squeeze risk: MODERATE
FINRA short sale data. FINRA short interest
Recent News & SEC Filings
- Bristol-Myers Squibb vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026?
- Bristol Myers Squibb’s 4.2% Dividend Yield Comes With a Trade-Off Investors Should Know
- Bristol Myers Squibb’s Rally Has Momentum, but Can Its New Drugs Justify More Upside?
- How Positive Phase 3 Results Will Impact Bristol Myers Squibb Stock Investors
- Bristol-Myers Squibb's Pulmonary Fibrosis Treatment Still Viable Despite Recent Mixed Phase 3 Results, UBS Says
- How Mixed Admilparant Results and Strong Oncology Data Will Impact Bristol Myers Squibb (BMY) Investors
- Neuroendocrine Prostate Cancer Market to Witness Growth at a 25% CAGR by 2036 Due to the Emergence of Emerging agents, including DLL3-targeted Therapies, ADCs, BsAbs, CAR-Ts, Aurora Kinase Inhibitors, and EZH2 Inhibitors | DelveInsight
- Hype vs. reality: What pharma’s hottest R&D bets have actually proved
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Bristol-Myers Squibb.
Full BMY Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.